Transforming breakthrough biology into life-changing medicines for cancer patients
Vivace Therapeutics is developing innovative cancer therapies with the goal of helping patients live longer, healthier lives. Our lead program, VT3989, is being evaluated as a potential new treatment for people with advanced mesothelioma, where better options are urgently needed.
VT3989, Vivace’s lead compound, is an orally bioavailable, once-daily, small molecule designed to disrupt YAP/TEAD-mediated transcription—an important growth and survival pathway on which certain tumors may depend. By selectively targeting this pathway, VT3989 has the potential to inhibit tumor growth while limiting effects on healthy tissue.
Mesothelioma is a rare, aggressive cancer that develops in the tissue lining the lungs, abdomen, or, less commonly, the heart. It is often diagnosed at an advanced stage and is associated with a poor prognosis and limited treatment options, particularly after standard therapies stop working.
Building on clinical data from its Phase 2 program, Vivace is preparing to advance VT3989 into a Phase 3 study. Our aim is to deliver a meaningful new treatment option for patients while establishing YAP/TEAD inhibition as a potentially important new approach in cancer care.
VT3989 has shown promising monotherapy activity in mesothelioma and offers broader development potential through combination strategies designed to address multiple solid-tumor indications.
